{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:06:40Z","timestamp":1792620400137,"version":"4.5.0"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T00:00:00Z","timestamp":1401926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) infections are a major cause of disease among immunocompromised patients. Prolonged antiviral therapy is often necessary to prevent or treat <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease, and may lead to development of antiviral resistance (<jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content>). Timely identification of viral mutations conferring resistance is essential for effective patient management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Amplification by polymerase chain reaction followed by bi\u2010directional nucleotide sequencing was performed for relevant regions of the <jats:styled-content style=\"fixed-case\">CMV UL<\/jats:styled-content>97 and <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>54 genes. Results from 570 samples submitted to a commercial reference laboratory for testing were reviewed and characterized with respect to the frequency of mutations detected, association with viral load (<jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content>), and consistency of results in a subset of patients with multiple samples. Only <jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> mutations confirmed by marker transfer experiments were included in the analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> mutations were identified in 176 (30.9%) of the 570 samples evaluated. A total of 17 different <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>97 mutations and 29 different <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>54 mutations were detected. A single mutation per sample was most commonly observed, although 61 samples (10.7%) had &gt;1 mutation, with 40 samples (7.0%) having mutations in both <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>97 and <jats:styled-content style=\"fixed-case\">UL<\/jats:styled-content>54 genes. The <jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content> of samples with <jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> mutations ranged from 2.03\u20137.15 log<jats:sub>10<\/jats:sub> copies\/mL, and the <jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content> did not differ significantly from samples without <jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> mutations. A subset of patients (<jats:italic>N<\/jats:italic>\u00a0=\u00a085) had &gt;1 sample tested, and 48.2% of these patients returned the same result for each sample analyzed, while the remainder had a different results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Genomic mutations conferring resistance in <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> to antiviral drugs were commonly identified in samples submitted from clinical patients to a reference laboratory for <jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> testing. Mutations were identified over the full range of <jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content>s and no correlation was identified between <jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content> and the presence of <jats:styled-content style=\"fixed-case\">AVR<\/jats:styled-content> mutations. In patients with multiple samples submitted for analysis, approximately half of the patients had samples with variable results when the initial result was compared to subsequent results.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12241","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T12:04:41Z","timestamp":1401969881000},"page":"561-567","source":"Crossref","is-referenced-by-count":38,"title":["Cytomegalovirus antiviral resistance: characterization of results from clinical specimens"],"prefix":"10.1111","volume":"16","author":[{"given":"S.","family":"Kleiboeker","sequence":"first","affiliation":[{"name":"Viracor\u2010IBT Laboratories Lee's Summit Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nutt","sequence":"additional","affiliation":[{"name":"Viracor\u2010IBT Laboratories Lee's Summit Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schindel","sequence":"additional","affiliation":[{"name":"Viracor\u2010IBT Laboratories Lee's Summit Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dannehl","sequence":"additional","affiliation":[{"name":"Viracor\u2010IBT Laboratories Lee's Summit Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hester","sequence":"additional","affiliation":[{"name":"Viracor\u2010IBT Laboratories Lee's Summit Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,5]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45449"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-10"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32834cfb58"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.00004.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12103"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/650463"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00584.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31821fad25"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00015-13"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/432012"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12241","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:59:58Z","timestamp":1695567598000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,5]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/tid.12241"],"URL":"https:\/\/doi.org\/10.1111\/tid.12241","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,5]]}}}